Emergent BioSolutions Files 8-K on Financials

Ticker: EBS · Form: 8-K · Filed: Oct 29, 2025 · CIK: 1367644

Emergent Biosolutions Inc. 8-K Filing Summary
FieldDetail
CompanyEmergent Biosolutions Inc. (EBS)
Form Type8-K
Filed DateOct 29, 2025
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, results-of-operations, disclosure

TL;DR

Emergent BioSolutions dropped an 8-K on 10/29/25 covering financials and other disclosures.

AI Summary

Emergent BioSolutions Inc. filed an 8-K on October 29, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and headquartered in Gaithersburg, Maryland.

Why It Matters

This filing provides crucial updates on Emergent BioSolutions' financial performance and operational status, which can impact investor decisions and market perception.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can significantly affect a company's stock price, necessitating careful review by investors.

Key Players & Entities

  • Emergent BioSolutions Inc. (company) — Registrant
  • October 29, 2025 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • 300 Professional Drive, Gaithersburg, Maryland 20879 (address) — Principal executive offices
  • 240-631-3200 (phone_number) — Registrant's telephone number

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is primarily to report on Emergent BioSolutions Inc.'s results of operations and financial condition, along with Regulation FD disclosures and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on October 29, 2025.

Where is Emergent BioSolutions Inc. headquartered?

Emergent BioSolutions Inc.'s principal executive offices are located at 300 Professional Drive, Gaithersburg, Maryland 20879.

What is the company's state of incorporation?

The company is incorporated in Delaware.

What is the registrant's telephone number?

The registrant's telephone number is (240) 631-3200.

Filing Stats: 672 words · 3 min read · ~2 pages · Grade level 9.2 · Accepted 2025-10-29 16:19:01

Key Financial Figures

  • $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On October 29, 2025, Emergent BioSolutions Inc. (the "Company") issued a press release (the "Press Release") announcing its financial and operating results for the quarter ended September 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Form 8-K") and is incorporated herein by reference.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On October 29, 2025, the Company will host a conference call to discuss its financial and operating results for the quarter ended September 30, 2025. The Company will use presentation materials in connection with this conference call (the "Earnings Call Slides"), which will be posted on the Company's website at www.emergentbiosolutions.com . A copy of the Earnings Call Slides is furnished as Exhibit 99.2 to this Form 8-K and is incorporated herein by reference. Information on the Company's website is not, and will not be deemed to be, a part of this Form 8-K or incorporated into any other filings the Company may make with the U.S. Securities and Exchange Commission. The information contained in Items 2.02 and 7.01 of this Form 8-K and Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions Inc. on October 29 , 2025. 99.2 Earnings Call Slides, dated October 29 , 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: October 29, 2025 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.